Data as of 3:28pm ET
| +0.02 / +0.88%|
NuPathe Inc. is a biopharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system, including neurological and psychiatric disorders. Its lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. The company has two other proprietary product candidates in preclinical development that address large market opportunities: NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. NuPathe was founded by Terri B. Sebree and Jane H. Hollingsworth on January 7, 2005 and is headquartered in Conshohocken, PA.
|Armando Anido||Chief Executive Officer & Director|
|Terri B. Sebree||President|
|Ezra H. Felker||Vice President-Operations|
|Keith Alan Goldan||Chief Financial Officer & Senior Vice President|
|Mark W. Pierce||Chief Scientific Officer & Vice President|